CGTXCognition TherapeuticsCGTX info
$0.58info27.47%24h
Global rank28630
Market cap$18.63M
Change 7d19.59%
YTD Performance-68.31%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Cognition Therapeutics (CGTX) Stock Overview

    Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.

    CGTX Stock Information

    Symbol
    CGTX
    Address
    2500 Westchester AvenuePurchase, NY 10577United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.cogrx.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    412 481 2210

    Cognition Therapeutics (CGTX) Price Chart

    -
    Value:-

    Cognition Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.57999998
    N/A
    Market Cap
    $18.63M
    N/A
    Shares Outstanding
    32.12M
    N/A
    Employees
    22.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org